GastroPlus在考特殊给药途径的应用文章 （2012—2020）

导  读

ROYAL皇家88娱乐技术部精取了2012-2020年10月GastroPlus在特殊给药途径领域的应用文章19篇。

其中编号1-4的文章是2019年8月-2020年10月新增的文章。

希望对您的业务或专业学习有所帮助。内容如下：

1.   采用生理药代动力学PBPK模型支持眼科悬浮制剂的开发

Physiologically Based Pharmacokinetic Model to Support Ophthalmic Suspension Product Development.

Le Merdy M, Tan ML, Babiskin AH, Zhao L. AAPS J. (2020) 22: 26. IF= 3.737

2.  用于利福平经皮递送的囊状弹性脂质体：体外，体内和GastroPlus™ 计算机预测研究

Vesicular elastic liposomes for transdermal delivery of rifampicin: In-vitro, in-vivo and in silico GastroPlus™ prediction studies.

Hussain A, Altamimi MA, Alshehri S, Imam SS, Singh SK. Eur J Pharm Sci. Volume 151, 1 August 2020, 105411. IF=3.616

3.  采用生理药代动力学PBPK建模，以了解利培酮口腔崩解膜剂的吸收机理

Physiologically based pharmacokinetic modeling to understand the absorption of risperidone orodispersible film.

Fang Chen, Hongrui Liu, Bing Wang, Liuliu Yang, Weimin Cai, Zheng Jiao, Zhou Yang, Yusheng Chen, Yingjun Quan, Xiaoqiang Xiang, Hao Wang. Front. Pharmacol.,03 February 2020. IF=4.545

4.   将吸入式气溶胶剂量测定法与生理药代动力学PBPK模型进行桥接，以评估尼古丁传递系统及其他物质的毒理

Bridging inhaled aerosol dosimetry to physiologically based pharmacokinetic modeling for toxicological assessment: nicotine delivery systems and beyond.

Kolli AR, Kuczaj AK, Martin F, Hayes AW, Peitsch MC, Hoeng J. Crit Rev Toxicol. Volume 49, 2019 - Issue 9. IF=4.257

5.  考察吸入粉雾剂DPI对湿度的敏感性：综合的体外-计算机预测进行风险的评估

Insights into DPI sensitivity to humidity: An integrated in-vitro-in-silico risk-assessment. 

Radivojev S, Pinto JT, Fröhlich E, Paudel A. J Drug Deliv Sci Technol.May 31, 2019. IF=2.606

6.   采用眼部机制性吸收建模与模拟，理解制剂处方性质对家兔眼部生物利用度的影响-以地塞米松Dexamethasone悬浮液为例

Application of Mechanistic Ocular Absorption Modeling and Simulation to Understand the Impact of Formulation Properties on Ophthalmic Bioavailability in Rabbits: a Case Study Using Dexamethasone Suspension.

Le Merdy M, Fan J, Bolger MB, Lukacova V, Spires J, Tsakalozou E, Patel V, Xu L, Stewart S, Chockalingam A, Narayanasamy S, Rouse R, Matta M, Babiskin AH, Kozak D. AAPS J. May 20, 2019. IF=3.545

7.  采用计算机预测的方法开发仿制药-装置组合的口服吸入制剂

In silico methods for development of generic drug‐device combination orally inhaled drug products. 

Walenga RL, Babiskin AH, Zhao L. CPT Pharmacometrics Syst Pharmacol. May 1, 2019. CiteScore=3.24

8.   眼部生物药剂学：建模和模拟方法对局部眼科制剂处方开发的影响

Ocular biopharmaceutics: impact of modeling and simulation on topical ophthalmic formulation development. 

Gukasyan HJ, Hailu S, Karami TK, Graham R. Drug Discov Today. Apr 5, 2019. IF=7.321

9.   用于了解吸入制剂在肺部暴露的实验和机制性计算模型的进展

Advances in experimental and mechanistic computational models to understand pulmonary exposure to inhaled drugs. 

Bäckman P, Arora S, Couet W, Forbes B, de Kruijf W, Paudel A. Eur J Pharm Sci. 2018 Feb 15;113:41-52. IF=3.616

10.  用现代标准评价2-乙基己基丙烯酸酯的皮肤致癌性研究

Critical Evaluation of 2-Ethylhexyl Acrylate Dermal Carcinogenicity Studies Using Contemporary Criteria. 

Murphy S, Ellis-Hutchings R, Finch L, Welz S, Wiench K.Toxicol Lett. Sep 15, 2018. IF=3.569

11.  化妆品安全评估中毒理学关注内部阈值（iTTC）面临的挑战：化妆品欧洲iTTC研讨会的相关讨论要点

Challenges in working towards an internal threshold of toxicological concern (iTTC) for use in the safety assessment of cosmetics: Discussions from the Cosmetics Europe iTTC Working Group workshop. 

Ellison CA, Blackburn KL, Carmichael PL, Clewell HJ 3rd, Cronin MTD, Desprez B, Escher SE, Ferguson SS, Gregoire SL, Hewitt NJ, Hollnagel HM, Klaric M, Patel A, Salhi S, Schepky A, Schmitt BG, Wambaugh JF, Worth A. Regul Toxicol Pharmacol. Jan 28, 2019. IF=2.652

12.  联用计算机模拟平台：计算流体动力学CFD和生理药代动力学PBPK的建模

Coupled in silico platform: Computational fluid dynamics (CFD) and physiologically-based pharmacokinetic (PBPK) modelling. 

Vulović A, Šušteršič T, Cvijić S, Ibrić S, Filipović N. Eur J Pharm Sci. 2018 Feb 15;113:171-184. IF=3.616

13.  肺部沉积和体外渗透对预测布地奈德吸入制剂血浆浓度的影响

Effect of the pulmonary deposition and in vitro permeability on the prediction of plasma levels of inhaled budesonide formulation. 

Salar-Behzadi S, Wu S, Mercuri A, Meindl C, Stranzinger S, Fröhlich E. Int J Pharm. 2017 Oct 30;532(1):337-344. IF=4.845

14.  用于表征口服吸入制剂PK的定量药理学模型

Pharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs. 

Borghardt JM, Weber B, Staab A, Kloft C. (2015). AAPS J. Apr 7. IF=3.737

15.  开发和验证雌二醇经皮给药系统的体内外相关性IVIVC模型

Development and validation of in vitro-in vivo correlation (IVIVC) for estradiol transdermal drug delivery systems. 

Yang Y, Manda P, Pavurala N, Khan MA, Krishnaiah YS. (2015). J Control Release. May 13;210:58-66. IF=7.727

16.  吸入制剂技术的发展进程：理解治疗的挑战，预测临床的疗效，并设计最佳的吸入制剂

Advances in Inhaled Technologies: Understanding the Therapeutic Challenge, Predicting Clinical Performance, and Designing the Optimal Inhaled Product. 

Bäckman P, Adelmann H, Petersson G, Jones CB. (2014) Clin Pharmacol Ther. 95(5):509-20. IF=6.565

17.  针对舌下给药的新型口腔房室吸收和转运模型的开发：以唑吡坦作为阐述的案例

Development of a Novel Oral Cavity Compartmental Absorption and Transit Model for Sublingual Administration: Illustration with Zolpidem. 

Xia B, Yang Z, Zhou H, Lukacova V, Zhu W, Milewski M, Kesisoglou F. (2015) AAPS J. Feb 26.IF=3.737

18.  普萘洛尔舌下缓冲片剂（Promptol™）的临床药代动力学-使用新的基于生理学模型进行吸收和处置的评价

Clinical Pharmacokinetics of Buffered Propranolol Sublingual Tablet (Promptol™)—Application of a New “Physiologically Based” Model to Assess Absorption and Disposition. 

Wang Y, Wang Z, Zuo Z, Tomlinson B, Lee BT, Bolger MB, Chow MS. (2013). AAPS J. Apr 19.IF=3.737.

19.  Risperdal®和 Consta® 微球体外释放的比较

Comparison of in vitro–in vivo release of Risperdal® Consta® microspheres. 

Rawata A, Bhardwajb U, Burgess DJ. (2012). Int. J. Pharm. 434(1):115-21.IF=4.845

点击查看其他文献

• GastroPlus在FDA等法规部门的应用文章(2016-2020)